Benzinga · Aug 10, 2026
Citigroup Maintains Buy on Ardelyx, Lowers Price Target to $11
Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $14 to $11.
AR
NASDAQ · ARDX
Ardelyx, Inc.
Healthcare · Biotechnology
$4.06
Up+$0.15 (+3.84%)
Updated Aug 15, 2026, 11:47 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.59B
- P/E ratio
- -25.9
- Dividend yield
- 0.00%
- 52-week range
- $3.86 – $7.43
- Volume
- 3.98M
- Avg. volume
- 4.57M
Price performance
ARDX price history
1M range · 21 trading sessions · Daily adjusted prices
ARDX closed at $4.06 after 21 trading sessions, down 21.92% for the selected period.
- Last close
- $4.06
- Period change
- -21.92%
- Period low
- $3.91
- Period high
- $5.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $3.93 | $4.07 | $3.86 | $4.06 | 3.98M |
| Aug 13, 2026 | $4.03 | $4.04 | $3.86 | $3.91 | 4.35M |
| Aug 12, 2026 | $3.94 | $4.009 | $3.89 | $3.97 | 4.95M |
| Aug 11, 2026 | $4.02 | $4.09 | $3.92 | $3.94 | 8.17M |
| Aug 10, 2026 | $4.05 | $4.12 | $3.90 | $4.00 | 10.81M |
| Aug 7, 2026 | $4.05 | $4.27 | $3.90 | $4.00 | 20.07M |
| Aug 6, 2026 | $4.89 | $5.00 | $4.815 | $4.87 | 7.28M |
| Aug 5, 2026 | $5.04 | $5.0989 | $4.84 | $4.91 | 3.11M |
| Aug 4, 2026 | $5.02 | $5.03 | $4.82 | $5.01 | 3.13M |
| Aug 3, 2026 | $4.98 | $5.025 | $4.88 | $4.98 | 2.92M |
| Jul 31, 2026 | $5.04 | $5.05 | $4.92 | $4.95 | 2.76M |
| Jul 30, 2026 | $4.97 | $5.04 | $4.905 | $5.04 | 2.59M |
| Jul 29, 2026 | $5.08 | $5.0963 | $4.97 | $5.00 | 2.18M |
| Jul 28, 2026 | $5.07 | $5.1249 | $5.025 | $5.085 | 1.66M |
| Jul 27, 2026 | $5.13 | $5.21 | $5.06 | $5.06 | 1.81M |
| Jul 24, 2026 | $5.15 | $5.17 | $5.02 | $5.03 | 1.72M |
| Jul 23, 2026 | $5.00 | $5.15 | $4.9689 | $5.13 | 2.07M |
| Jul 22, 2026 | $5.03 | $5.0942 | $5.004 | $5.08 | 2.18M |
| Jul 21, 2026 | $5.09 | $5.115 | $4.98 | $5.09 | 3.8M |
| Jul 20, 2026 | $5.23 | $5.27 | $5.08 | $5.09 | 2.37M |
| Jul 17, 2026 | $5.01 | $5.235 | $5.00 | $5.20 | 3.27M |
Latest ARDX news
The latest Smart Investors Daily articles mentioning ARDX.
Stock researchCompany · Overview
ARDX research
Overview
Company profile and research snapshot.
Company profile
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Citigroup | Buy | — |
| Aug 7, 2026 | BTIG | Buy | — |
| Aug 7, 2026 | TD Cowen | Buy | — |
| Feb 23, 2026 | Wedbush | Outperform | — |
| Feb 20, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
TD Cowen Maintains Buy on Ardelyx, Lowers Price Target to $10
TD Cowen analyst Joseph Thome maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $13 to $10.
SeekingAlpha · Aug 7, 2026
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsLisa CaperelliMichael Raab - President, CEO & DirectorEric...
Benzinga · Aug 7, 2026
BTIG Maintains Buy on Ardelyx, Lowers Price Target to $14
BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $17 to $14.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
